The therapeutic relevance of targeting FSP1 is highlighted in certain contexts, such as Keap1-mutant lung cancers (e.g., H460, A549), where FSP1 is highly expressed and GPX4 levels are low, suggesting that FSP1 inhibition could be a particularly effective strategy in these tumors [83]. This evidence concerns the gene GPX4 and lung carcinoma.